Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Entry into a Material Definitive Agreement On August 20, 2026, Starling Oncology Management, Limited Liability Company, a wholly owned subsidiary of Starling Oncology, Inc. (“SOM, LLC”), entered into a Credit Agreement (the “Revolving Loan Agreement”) among SOM, LLC, such other persons joined thereto as a borrower from time to time, and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender. The Revolving Loan Agreement provides access to a revolving line of credit facility in the…

Results of Operations and Financial Condition On August 6, 2026, Starling Oncology, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2026 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in

Unregistered Sales of Equity Securities. On July 1, 2026, as a part of the repayment of the 2027 Convertible Notes, the Company issued warrant agreements to purchase shares of common stock of the Company (the “Warrants”) to Deerfield Partners, L.P. and its affiliates, with an expiration date of August 9, 2027 and an initial exercise price of $8.567 per share. The total number of shares of common stock underlying the Warrants is 10,025,535 shares. No additional consideration was paid to the Co…

Entry into a Material Definitive Agreement Term Loan Agreement On July 1, 2026, The Oncology Institute, Inc. (the “Company”) entered into a Credit Agreement (the “Term Loan Agreement”), by and among the Company, the lenders from time to time party thereto, and Orbimed Opportunities (CA) V LLC, as the initial lender and administrative agent. The Term Loan Agreement provides for a term loan facility in an aggregate principal amount of $75 million, which was drawn in full on the date of entry in…

Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

of a Current Report on Form 8-K filed on November 6, 2025, regarding a cybersecurity incident affecting a software service provider (“Vendor”) utilized by the Company. At the time of the prior voluntary disclosure, the Vendor had indicated that investigation was still ongoing and it could not yet confirm any evidence that any patient personal information was compromised as a result of this incident. However, on May 20, 2026, Kroll, who is the third-party administrator for the Vendor, notified…

Results of Operations and Financial Condition On May 7, 2026, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in

Results of Operations and Financial Condition On March 12, 2026, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in

Director — Kimberly Tzoumakas: Appointment of Kimberly Tzoumakas to the Board of Directors.

Results of Operations and Financial Condition. On January 12, 2026, The Oncology Institute, Inc. (the “Company”) issued a press release reaffirming the Company’s 2025 financial guidance and providing the Company’s preliminary 2026 financial outlook and certain additional longer-term financial guidance. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in this Item 2.02, including Exhibit 99.1, is furnished and…

Director — Mark D. Stolper: Appointment of a new independent director with specific expertise to the Audit Committee.

Director — Gabriel Ling: Mr. Ling resigned from the Board of Directors.

Results of Operations and Financial Condition On November 13, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in

Regulation FD Disclosure. On November 3, 2025, The Oncology Institute, Inc. (the “Company”) determined that a cybersecurity incident affecting an information technology software provider would potentially delay fee-for-service collections. Based on the Company's current assessment, this incident is expected to result in a brief immaterial delay in the collection of some claims in the Company's fee-for-service segment. To date, the software provider has not indicated to the Company that there…

Results of Operations and Financial Condition On August 13, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in

Director — Richard Barasch: Mr. Barasch resigned from the Board of Directors.

Results of Operations and Financial Condition On May 14, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in

Chief Operating Officer — Jeremy Castle: Mr. Castle resigned as Chief Operating Officer.

Entry into a Material Definitive Agreement. On March 26, 2025, The Oncology Institute, Inc. (the “Company”) closed its previously announced private placement (the “Private Placement”) of an aggregate of: (i) 12,006,510 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,886,614 shares of Common Stock and (iii) accompanying common warrants (the “Common War…

The offer and sale of the Securities, the shares of Preferred Stock and the shares of Common Stock underlying the Warrants and shares of Preferred Stock have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). The Company issued the Securities and shares of Preferred Stock in reliance on exemptions from registration provided for under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, or in the case of the Exchange Section 3(a)(9) of the S…

Regulation FD Disclosure. On March 24, 2025, the Company issued a press release announcing the Private Placement and the Exchange, a copy of which is attached as Exhibit 99.1 hereto and incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and such information shall not be deemed to be incor…

Material Modification to Rights of Security Holders To the extent required by

The offer and sale of the Securities, the shares of Preferred Stock and the shares of Common Stock underlying the Warrants and shares of Preferred Stock have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). The Company issued the Securities and shares of Preferred Stock in reliance on exemptions from registration provided for under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, or in the case of the Exchange Section 3(a)(9) of the S…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 24, 2025, The Oncology Institute, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), including existing investors, as well as members of the Company’s management team and board of directors, and entities affiliates with members of the Company’s board of directors. The Purchase Agreement provides for the sale and issuance by the…